Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice

Neuroscience Letters

Volumn 234, Issue 2-3, 1997, Pages 123-126

  Boireau, Alain ^a   Bordier, Françoise ^a   Dubédat, Pierre ^a   Pény, Colette ^a   Impérato, Assunta ^a  

^a SANOFI   (France)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Cytokines; Dopamine; Neurotoxicity; Parkinson's disease; Thalidomide

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG EFFECT; INFLAMMATORY CELL; MACROPHAGE ACTIVATION; MICROGLIA; MOUSE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STRIATE CORTEX; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANTI-INFLAMMATORY AGENTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMOVANILLIC ACID; HYPNOTICS AND SEDATIVES; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED C57BL; PARKINSON DISEASE; THALIDOMIDE;

EID: 0030773331     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(97)00685-X     Document Type: Article

References (29)

1. Agid, Y., Ruberg, M., Javoy-Agid, F., Hirsh, E., Raisman-Vozari, R., Vyas, S., Faucheux, B., Michel, P., Kastner, A., Blanchard, V., Damier, P., Villares, J. and Zhang, P., Are dopaminergic neurons selectively vulnerable to Parkinson's disease? In H. Narabayashi, T. Nagatsu, N. Yanagisawa and Y. Mizuno (Eds.), Parkinson's Disease from Basic Research to Treatment, Advance in Neurology, Vol. 60, Raven Press, New York, 1993, pp. 148-164.
2. Boireau A., Dubédat P., Bordier F., Peny C., Miquet J.M., Durand G., Meunier M., Doble A. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. NeuroReport. 5:1994;2657-2660.
3. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., Hirsh E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172:1994;151-154.
4. Brouillet E., Beal M.F. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. NeuroReport. 4:1993;387-390.
5. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.J., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA. 80:1983;4546-4550.
6. Czlonkowska A., Kohutnicka M., Kurkowska-Jastrzebska I., Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration. 5:1996;137-143.
7. Davis G.C., Williams A.C., Markey S.P., Hebert M.H., Caine E.D., Reichert C.M., Kopin I.J. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatr. Res. 1:1979;249-254.
8. Fornai F., Alessandri M.G., Fascetti F., Vaglini F., Corsini G.U. Clonidine suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced reductions of striatal dopamine and tyrosine hydroxylase activity in mice. J. Neurochem. 65:1995;704-709.
9. Gerlach M., Ben-Sachard D., Riederer P., Youdim M.B.H. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63:1994;793-807.
10. Greten T.F., Sinha B., Haslberger C., Eigler A., Endres S. Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-α synthesis. Eur. J. Pharmacol. 299:1996;229-233.
11. Hétier E., Boireau A., Dubédat P., Blanchard J.-C. Neurotensin effects on evoked release of dopamine in slices from striatum, nucleus accumbens and prefrontal cortex in rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 227:1988;13-17.
12. Hulley P., Hartikka J., Abdel'al S., Engels P., Buerki H.-R., Wiederhold K.-H., Müller T., Kelly P., Lowe D., Lübbert H. Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. Eur. J. Neurosci. 7:1995;2431-2440.
13. + by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin MPTP. Eur. J. Pharmacol. 106:1985;455-456.
14. Jones-Humble S.A., Morgan P.F., Cooper B.R. The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease. Life Sci. 54:1994;245-252.
15. Kopin, I.J., Mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced destruction of dopaminergic neurons. In H. Herken and F. Hucho (Eds.), Selective Neurotoxicity, Vol. 102, Springer-Verlag, Berlin, 1992, pp. 333-356.
16. Langston J.W., Ballard P.A., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of mepiridine-analog synthesis. Science. 219:1983;979-980.
17. Lau Y.-S., Mouradian M.M. Protection against acute MPTP-induced dopamine depletion in mice by adenosine A1 agonist. J. Neurochem. 60:1993;768-771.
18. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38:1988;1285-1291.
19. Melamed E., Martinovits G., Pikarsky E., Rosenthal J., Uzzan A. Diphenylhydanthoin and phenobarbital suppress the dopaminergic neurotoxicity of MPTP in mice. Eur. J. Pharmacol. 128:1986;255-257.
20. Mizuno Y., Mori H., Kondo T. Potential of neuroprotective therapy in Parkinson's disease. CNS Drugs. 1:1994;45-56.
21. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-(are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180:1994;147-150.
22. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165:1994;208-210.
23. Moncada B., Baranda M.L., Gonzalez-Amaro R., Urbina R., Loredo C.E. Thalidomide-effect on T cell subsets as a possible mechanism of action. Int. J. Lepr. 53:1985;201-205.
24. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J. Exp. Med. 177:1993;1675-1680.
25. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
26. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J. Exp. Med. 173:1991;699-703.
27. Schulz J.B., Matthews R.T., Muqit M.M.K., Browne S.E., Beal F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64:1995;936-939.
28. Somers G.F. Pharmacological properties of thalidomide (α-phtalimido glutarimide), a new sedative hypnotic drug. Br. J. Pharmacol. 15:1960;111-116.
29. Tabatabaei A., Perry T.L., Hansen S., Krieger C. Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice. Neurosci. Lett. 1412:1992;192-194.